ITN (Innovative Training Network)
Predict is funded by the Marie Skłodowska-Curie Actions, part of the EU’s Horizon 2020 Programme. Grant Agreement No 766276.
01/10/2017 – 30/09/2021 (4 years)
Maastricht UniversityVIEW PARTNERS >
Fondazione IRCCS Istituto Nazionale dei Tumori
Université de Liège
Erasmus University Medical Centre Rotterdam
Deutsches Krebsforschungszentrum Heidelberg
Institut National de la Santé et de la Recherche Médicale
Mirada Medical LTD
Perspectum Diagnostics LTD
Health Innovation Ventures BV
European Cancer Patient Coalition (ECPC)
Università Cattolica S. Cuore, Rome
Heidelberg Ion Beam Therapy Center GMBH
Why it matters
Tumour cells can differ greatly both between patients (inter-tumour heterogeneity) and within patients (intra-tumour heterogeneity). These differences affect how patients respond to cancer therapy and hamper wide deployment of personalised medicine for cancer treatment. PREDICT educates 15 Early Stage Researchers (ESRs) in the fields of radiomics and personalised medicine, training them to analyse large amounts of radiographic images to determine tumour heterogeneity and predict how patients will respond to treatment.
What ECPC does
ECPC provides the Early Stage Researchers with training courses and workshops on communicating complex research results to a public audience, understanding the patient perspective, and scientific writing. ECPC uses its communication channels to share information about the project, its results and its participants. ECPC is represented on the Project Advisory Board to monitor project progress and provide input on the design and overall direction.
This project is funded by the European Union